Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  gallium Ga 68-edotreotide
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-6 of 6 for your search:
Start Over
Gallium-68 DOTATOC for Management of Neuroendocrine Tumors
Phase: Phase III
Type: Diagnostic, Health services research
Status: Approved-not yet active
Age: Not specified
Sponsor: Other
Protocol IDs: 15-999, NCT02375464
Ga-68-DOTATOC -PET in the Management of Pituitary Tumours
Phase: Phase III
Type: Biomarker/Laboratory analysis, Diagnostic
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Ga-PET version 8 (141017), 2010-020482-24, NCT02419664
Evaluation of Gallium-68 DOTA-TOC Imaging of Somatostatin Receptor Positive Malignancies
Phase: Phase II
Type: Diagnostic
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: UCSF-DOTA-TOC, NCT02177773
Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
Phase: Phase II
Type: Diagnostic
Status: Approved-not yet active
Age: 6 months and over
Sponsor: Other
Protocol IDs: 201503708, NCT02441062
Gallium Ga 68-Edotreotide PET/CT Compared With Indium In 111 Pentetreotide Plus Contrast-Enhanced CT (or MRI) in Diagnosing Patients With Neuroendocrine Tumors and Other Somatostatin Receptor Positive Tumors
Phase: No phase specified
Type: Diagnostic
Status: Active
Age: 2 and over
Sponsor: NCI, Other
Protocol IDs: 201212736, NCI-2013-00936, P30CA086862, R01CA167632, NCT01869725
PET-CT Imaging of Neuro-endocrine Tumors and Preliminary Clinical Evaluation
Phase: No phase specified
Type: Diagnostic
Status: Active
Age: 18 and older
Sponsor: Other
Protocol IDs: CHUBX2012/28, 2013-003927-12, NCT02134639
Start Over